Identifying COPD patients at increased risk of mortality: Predictive value of clinical study baseline data

Respiratory Medicine

Volumn 102, Issue 11, 2008, Pages 1615-1624

  Halpin, David M G ^a   Peterson, Stefan ^b   Larsson, Thomas P ^b   Calverley, Peter M A ^c  

^a ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Budesonide formoterol; Health status; Inhaled corticosteroids; Long acting 2 agonists; Mortality; SGRQ

Indexed keywords

BUDESONIDE; FORMOTEROL; PREDNISOLONE; STEROID; TERBUTALINE; TURBUHALER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SHORT FORM 36; SMOKING; ST. GEORGE RESPIRATORY QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; BUDESONIDE; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RESPIRATORY FUNCTION TESTS; RISK FACTORS;

EID: 55549111184     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.05.007     Document Type: Article

References (35)

1. Lopez A.D., Shibuya K., Rao C., Mathers C.D., Hansell A.L., Held L.S., et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27 (2006) 397-412
2. Anthonisen N.R., Skeans M.A., Wise R.A., Manfreda J., Kanner R.E., and Connett J.E. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 (2005) 233-239
3. Landbo C., Prescott E., Lange P., Vestbo J., and Almdal T.P. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 (1999) 1856-1861
4. Ries A.L., Kaplan R.M., Limberg T.M., and Prewitt L.M. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 122 (1995) 823-832
5. Oga T., Nishimura K., Tsukino M., Sato S., and Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 167 (2003) 544-549
6. Vestbo J. What is an exacerbation of COPD?. Eur Respir Rev 13 (2004) 6-13
7. Chu C.M., Chan V.L., Lin A.W., Wong I.W., Leung W.S., and Lai C.K. Readmission rates and life threatening events in COPD survivors treated with non-invasive ventilation for acute hypercapnic respiratory failure. Thorax 59 (2004) 1020-1025
8. Jones P.W., Quirk F.H., and Baveystock C.M. The St George's Respiratory Questionnaire. Respir Med 85 Suppl. B (1991) 25-31
9. Celli B.R., Cote C.G., Marin J.M., Casanova C., Montes de Oca M., Mendez R.A., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350 (2004) 1005-1012
10. Calverley P.M., Boonsawat W., Cseke Z., Zhong N., Peterson S., and Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22 (2003) 912-919
11. Szafranski W., Cukier A., Ramirez A., Menga G., Sansores R., Nahabedian S., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 74-81
12. Calverley P.M.A., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
13. Tkacova R., Toth S., and Sin D.D. Inhaled corticosteroids and survival in COPD patients receiving long-term home oxygen therapy. Respir Med 100 (2006) 385-392
14. Kiri V.A., Pride N.B., Soriano J.B., and Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 172 (2005) 460-464
15. Sin D.D., Wu L., Anderson J.A., Anthonisen N.R., Buist A.S., Burge P.S., et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60 (2005) 992-997
16. Wedzicha J.A., Calverley P.M., Seemungal T.A., Hagan G., Ansari Z., and Stockley R.A. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177 (2008) 19-26
17. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2007). Available at: http://www.goldcopd.com/Guidelineitem.asp?l1=2&;l2=1&;intId?989 (accessed April 2008)
18. Collett D. Modelling survival data in medical research (1994), Chapman and Hall/CRC, Florida
19. Schwarz G. Estimating the dimension of a model. Ann Stat 6 (1978) 461-464
20. Schafer J.L. Analysis of incomplete multivariate data (1997), Chapman & Hall/CRC, London
21. Therneau T.M., and Grambsch P.M. Modeling survival data: extending the Cox model (2000), Springer Verlag, New York
22. Adams K.F., Schatzkin A., Harris T.B., Kipnis V., Mouw T., Ballard-Barbash R., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 355 (2006) 763-778
23. Martinussen T., and Scheike T.H. Dynamic regression models for survival data (2006), Springer Verlag, New York
24. Oga T., Nishimura K., Tsukino M., Sato S., Hajiro T., and Mishima M. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med 101 (2007) 146-153
25. Domingo-Salvany A., Lamarca R., Ferrer M., Garcia-Aymerich J., Alonso J., Félez M., et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166 (2002) 680-685
26. Gudmundsson G., Gislason T., Lindberg E., Hallin R., Ulrik C.S., Brøndum E., et al. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res 7 (2006) 109
27. Almagro P., Calbo E., Ochoa de Echaguen A., Barreiro B., Quintana S., Heredia J.L., et al. Mortality after hospitalization for COPD. Chest 121 (2002) 1441-1448
28. Gerardi D.A., Lovett L., Benoit-Connors M.L., Reardon J.Z., and ZuWallack R.L. Variables related to increased mortality following out-patient pulmonary rehabilitation. Eur Respir J 9 (1996) 431-435
29. Schols A.M., Slangen J., Volovics L., and Wouters E.F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 (1998) 1791-1797
30. Osman I.M., Godden D.J., Friend J.A., Legge J.S., and Douglas J.G. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 52 (1997) 67-71
31. Salpeter S.R., Buckley N.S., and Salpeter E.E. Meta-analysis: anticholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 21 (2006) 1011-1019
32. Macie C., Wooldrage K., Manfreda J., and Anthonisen N.R. Inhaled corticosteroids and mortality in COPD. Chest 130 (2006) 640-646
33. Lofdahl C.G., Postma D.S., Pride N.B., Boe J., and Thoren A. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J 29 (2007) 1115-1119
34. Calverley P.M., and Scott S. Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events?. COPD 3 (2006) 233-242
35. Kesten S., Plautz M., Piquette C.A., Habib M.P., and Niewoehner D.E. Premature discontinuation of patients: a potential bias in COPD clinical trials. Eur Respir J 30 (2007) 898-906